PubMed:22862926 JSONTXT

{"project":"Allie","denotations":[{"id":"SS1_22862926_1_0","span":{"begin":225,"end":254},"obj":"expanded"},{"id":"SS2_22862926_1_0","span":{"begin":256,"end":262},"obj":"abbr"},{"id":"SS1_22862926_1_1","span":{"begin":311,"end":355},"obj":"expanded"},{"id":"SS2_22862926_1_1","span":{"begin":357,"end":360},"obj":"abbr"},{"id":"SS1_22862926_1_2","span":{"begin":363,"end":386},"obj":"expanded"},{"id":"SS2_22862926_1_2","span":{"begin":388,"end":393},"obj":"abbr"},{"id":"SS1_22862926_2_0","span":{"begin":488,"end":515},"obj":"expanded"},{"id":"SS2_22862926_2_0","span":{"begin":517,"end":521},"obj":"abbr"}],"relations":[{"id":"AE1_22862926_1_0","pred":"abbreviatedTo","subj":"SS1_22862926_1_0","obj":"SS2_22862926_1_0"},{"id":"AE1_22862926_1_1","pred":"abbreviatedTo","subj":"SS1_22862926_1_1","obj":"SS2_22862926_1_1"},{"id":"AE1_22862926_1_2","pred":"abbreviatedTo","subj":"SS1_22862926_1_2","obj":"SS2_22862926_1_2"},{"id":"AE1_22862926_2_0","pred":"abbreviatedTo","subj":"SS1_22862926_2_0","obj":"SS2_22862926_2_0"}],"text":"Incretin and pancreatic hormone secretion in Caucasian non-diabetic carriers of the TCF7L2 rs7903146 risk T allele.\nWe characterised 62 non-diabetic, middle-aged, Caucasians with and without the T risk allele of rs7903146 in transcription factor 7-like 2 (TCF7L2) with regard to secretion of insulin, glucagon, glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) as well as insulin sensitivity and endogenous glucose production. All participants had a 3-h oral glucose tolerance test (OGTT), an intravenous glucose tolerance test and a euglycaemic, hyperinsulinaemic clamp. After adjustment for age and sex, risk T allele carriers had higher haemoglobin A1c levels (p = 0.030), reduced first-phase insulin response (p = 0.048), higher peripheral insulin sensitivity (p = 0.050) and lower fasting GIP concentrations (p = 0.003) than CC allele carriers. The latter was also reflected by lower total GIP secretion during the OGTT (p = 0.018). We found no significant differences in endogenous glucose production, hepatic insulin sensitivity or fasting concentrations of glucose, insulin, glucagon and GLP-1 between the groups. The findings suggest that the effect of TCF7L2 on diabetes risk may include reduced secretion of GIP."}

{"project":"CHEMDNER-training-test","denotations":[{"id":"T1","span":{"begin":311,"end":318},"obj":"TRIVIAL"},{"id":"T2","span":{"begin":441,"end":448},"obj":"TRIVIAL"},{"id":"T3","span":{"begin":493,"end":500},"obj":"TRIVIAL"},{"id":"T4","span":{"begin":539,"end":546},"obj":"TRIVIAL"},{"id":"T5","span":{"begin":1022,"end":1029},"obj":"TRIVIAL"},{"id":"T6","span":{"begin":1099,"end":1106},"obj":"TRIVIAL"}],"text":"Incretin and pancreatic hormone secretion in Caucasian non-diabetic carriers of the TCF7L2 rs7903146 risk T allele.\nWe characterised 62 non-diabetic, middle-aged, Caucasians with and without the T risk allele of rs7903146 in transcription factor 7-like 2 (TCF7L2) with regard to secretion of insulin, glucagon, glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) as well as insulin sensitivity and endogenous glucose production. All participants had a 3-h oral glucose tolerance test (OGTT), an intravenous glucose tolerance test and a euglycaemic, hyperinsulinaemic clamp. After adjustment for age and sex, risk T allele carriers had higher haemoglobin A1c levels (p = 0.030), reduced first-phase insulin response (p = 0.048), higher peripheral insulin sensitivity (p = 0.050) and lower fasting GIP concentrations (p = 0.003) than CC allele carriers. The latter was also reflected by lower total GIP secretion during the OGTT (p = 0.018). We found no significant differences in endogenous glucose production, hepatic insulin sensitivity or fasting concentrations of glucose, insulin, glucagon and GLP-1 between the groups. The findings suggest that the effect of TCF7L2 on diabetes risk may include reduced secretion of GIP."}

{"project":"PubTator4TogoVar","denotations":[{"id":"5","span":{"begin":91,"end":100},"obj":"SNP"},{"id":"34","span":{"begin":212,"end":221},"obj":"SNP"}],"attributes":[{"id":"A5","pred":"resolved_to","subj":"5","obj":"tmVar:rs7903146;VariantGroup:0;CorrespondingGene:6934;RS#:7903146;CorrespondingSpecies:9606"},{"id":"A34","pred":"resolved_to","subj":"34","obj":"tmVar:rs7903146;VariantGroup:0;CorrespondingGene:6934;RS#:7903146;CorrespondingSpecies:9606"}],"text":"Incretin and pancreatic hormone secretion in Caucasian non-diabetic carriers of the TCF7L2 rs7903146 risk T allele.\nWe characterised 62 non-diabetic, middle-aged, Caucasians with and without the T risk allele of rs7903146 in transcription factor 7-like 2 (TCF7L2) with regard to secretion of insulin, glucagon, glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) as well as insulin sensitivity and endogenous glucose production. All participants had a 3-h oral glucose tolerance test (OGTT), an intravenous glucose tolerance test and a euglycaemic, hyperinsulinaemic clamp. After adjustment for age and sex, risk T allele carriers had higher haemoglobin A1c levels (p = 0.030), reduced first-phase insulin response (p = 0.048), higher peripheral insulin sensitivity (p = 0.050) and lower fasting GIP concentrations (p = 0.003) than CC allele carriers. The latter was also reflected by lower total GIP secretion during the OGTT (p = 0.018). We found no significant differences in endogenous glucose production, hepatic insulin sensitivity or fasting concentrations of glucose, insulin, glucagon and GLP-1 between the groups. The findings suggest that the effect of TCF7L2 on diabetes risk may include reduced secretion of GIP."}

{"project":"PubTatorOnTogoVar","denotations":[{"id":"5","span":{"begin":91,"end":100},"obj":"SNP"},{"id":"34","span":{"begin":212,"end":221},"obj":"SNP"},{"id":"T1","span":{"begin":91,"end":100},"obj":"SNP"},{"id":"T1","span":{"begin":212,"end":221},"obj":"SNP"}],"attributes":[{"id":"A5","pred":"resolved_to","subj":"5","obj":"tmVar:rs7903146;VariantGroup:0;CorrespondingGene:6934;RS#:7903146;CorrespondingSpecies:9606"},{"id":"A34","pred":"resolved_to","subj":"34","obj":"tmVar:rs7903146;VariantGroup:0;CorrespondingGene:6934;RS#:7903146;CorrespondingSpecies:9606"},{"id":"A1","pred":"resolved_to","subj":"T1","obj":"tmVar:rs7903146;VariantGroup:0;CorrespondingGene:6934;RS#:7903146;CorrespondingSpecies:9606"},{"id":"A1","pred":"resolved_to","subj":"T1","obj":"tmVar:rs7903146;VariantGroup:0;CorrespondingGene:6934;RS#:7903146;CorrespondingSpecies:9606"}],"text":"Incretin and pancreatic hormone secretion in Caucasian non-diabetic carriers of the TCF7L2 rs7903146 risk T allele.\nWe characterised 62 non-diabetic, middle-aged, Caucasians with and without the T risk allele of rs7903146 in transcription factor 7-like 2 (TCF7L2) with regard to secretion of insulin, glucagon, glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) as well as insulin sensitivity and endogenous glucose production. All participants had a 3-h oral glucose tolerance test (OGTT), an intravenous glucose tolerance test and a euglycaemic, hyperinsulinaemic clamp. After adjustment for age and sex, risk T allele carriers had higher haemoglobin A1c levels (p = 0.030), reduced first-phase insulin response (p = 0.048), higher peripheral insulin sensitivity (p = 0.050) and lower fasting GIP concentrations (p = 0.003) than CC allele carriers. The latter was also reflected by lower total GIP secretion during the OGTT (p = 0.018). We found no significant differences in endogenous glucose production, hepatic insulin sensitivity or fasting concentrations of glucose, insulin, glucagon and GLP-1 between the groups. The findings suggest that the effect of TCF7L2 on diabetes risk may include reduced secretion of GIP."}